Congratulations once again on very strong results. Just a couple of questions from my side. First, have you signed or are looking to sign any new CDMO contract for the four products that have been validated you mentioned?
Okay. And would you be, let's say, I know you will not be giving out the names of the products, but would you be, let's say, signing the contract or no?
Just one from my side. I think, Mayank, you mentioned that you have offtake visibility from Q4 FY26. So, in that context, can you guide us for the order book status for FY27 and probably result in CSM growth in FY27?
Okay. And just one clarification. I think we have stopped giving the overheads and the gross margin for the Phar ma segment from this quarter. Can you please give us for the second quarter?
Thank you for the opportunity. Couple from my side, with strong 75% growth in the pharma business, do you expect pharma business will turn EBITDA positive in FY26 or if not in FY26, then when?
Got it. And on PIOXANILIPROLE, the new NCE, just wanted to understand which major crop would this insecticide be used on and which is the first country you intend to commercialize it?
Thank you for taking my question. So, firstly on agri-CSM business, how does your order book look like in CY25? As in, would that be able to give you a double- digit growth in, let's say, CY25 or FY26?
Noted sir. Fair point. Secondly, has there been any progress on our own AI, Pyroxene, Helipro, I mean, where are we in that? Has the registration started out? Which stage are we at?
By when do you think our recently acquired Plant Health Care business could turn EBITDA positive and does this quarter contain any one -off expenses from the acquisition?
Couple of questions. Firstly, on the PLA business. So, when is your internal estimate of EBIT level breakeven for the plant?
So, my point was like, because of INR 2,800 crore kind of a gross block, our depreciation at a 5%, 6% depreciation rate could be in the range of INR 150 odd crore or so. So, when I meant by EBIT level breakeven as in like EBITDA of 150 -150 getting offset with the depreciation. So, EBIT level breakeven. That way I was trying to understand when is it that your EBITDA will be higher than your depreciation?
So, a couple from my side. First, on the long-term debt for PLA that you have raised Rs. 460 crore, it is mentioned in presentation that repayments of the term loan will begin from Q3 FY29. So, till that time, there will be no interest outflow. Is that correct? And when will the 5% interest payment will start?
Okay, after the commencement. Okay, got it. And just as a continuation on the same point, what is the projected borrowing for FY28 and the expected interest outflow once PLA is up and running? Because I think you had mentioned it earlier in passing, so I just wanted to understand that better.
Yes, hi, sir. Thank you for the opportunity. Two questions from my side. First, on a standalone basis, given we are already almost halfway through the quarter, do you expect a volume growth to come back in 3Q and what about 4Q?
Okay, and secondly when are we expecting a decent contribution from barbituric acid lamivudine intermediate and Performance Chemical One?
Congrats on good set of numbers and breaking even in the subsid iary. Just a couple of points from my side. First, have you started the production of Barbituric acid?
And on the BHT, have you seen any contribution or not yet?
Congratulations on a very strong set of numbers. Two questions from my side. First, on the ag chem intermediate, the new ag chem intermediate product. So can you please highlight the expected peak market size of the agrochemical for which you'll be manufac turing this intermediate?
No problem, and secondly, on the R32 incremental capacities -- so what kind of utilization rate that you are planning? Because I believe you said that you will be cautiously supplying to the market so that there is no oversupply. So what's the kind of utilization rate that you are planning for R32…
Congrats on very strong set of numbers. Two questions from my side. First, as per my understanding, production of electronic grade HF first requires gasification of anhydrous HF. So would the tech tie-up enable us to do the same? Or have you developed that in-house?
So I was just asking the gasification of the anhydrous HF is required in production of electronic grade HF, So the tie-up that you have done?
Sir, congrats on very strong set of numbers. Just 2 questions from my side. Firstly, on this INR30 crores Surat capex. I just wanted to understand what the sales be gradual in FY '26 and peak in FY '27? How that is...
Understood. And on the CDMO side in the presentation, you mentioned that U.S. major, the scale-up order received. So is it like a new contract that you are in the midst of signing or how is it, can you please share some details there?
Hi, sir. Thank you for taking my question. A couple from my side. First, just a bo okkeeping question. What has led to decline in the other operating expenses during the quarter, which has resulted in EBITDA margin expansion?
So, this Rs. 211 crores range is a sustainable range going ahead? Till the time our power expenses, probably the renewable thing comes in. But I think that is captured in the power expenses, not in other expenses.
Congrats on a good set of numbers. Two from my side. First, in your opening remarks, you mentioned that registration and scale-up of an AI is expected in FY26, so what is the status of the rest 4 to 5 AIs? Would there be a scale -up of any other AIs apart from the one that you mentioned in FY26?
Got it. And secondly, just on this Spec. Chem. side, what would be your domestic specialty chemical sales as a percentage of overall Spec. Chem. sales? A rough range would be helpful.
Congrats on the strong set of numbers. Firstly, just clarification, so this Rs. 2,850 crore of Fluorochemicals revenue in FY25, does that include the industrial chemicals revenue also? And what would be the number?
So just wanted to understand what was the industrial chemical revenue for the full year.
Congrats on good set of numbers. Just a couple of questions. So, firstly, when you mentioned large contribution from AI is expected in FY26, I just wanted to understand?
Fair enough, point taken. Sir, just what percentage of incremental spec-chem sales do you expect from AIs in FY26?
Yes. Hi, sir. Thanks for taking my question. Three from my side. First on the Carbon Black side, what is the volume growth headroom in FY '26 considering the time taken to bring the capacity downstream?
So, you do have growth headroom from that 90,000MT expansion that you are doing at Tamil Nadu, so from there you are expecting an incremental probably is 50,000 -60,000 MT, is that correct?
Hi, sir. Thank you for taking my question. So firstly, on Carbon Black , just on the destocking bit, do we not work on just-in-time model given high correlation with the crude?
Okay. Fair enough. And so, given the current scenario, by when do we expect to achieve, let's say, 160-170 KT, a kind of quarterly sales volume in Carbon Black business?
Firstly, on this additional DAP subsidy, Rs.3,500 per ton, how much have you received in this quarter?
So essentially, that Rs.500 per ton was pending for the last quarter and it is pending for this quarter as well. So the remaining amount could come through in the subsequent quarters. Is that the understanding?
If I just look at the standalone numbers, your inventories are somewhere worth 1,185 crores and if I calculate the inventory days in the standalone business, has jumped to more than 500 to 600 days. Can you elaborate please what is going there?
But if I just look at second half of last year to second half of let's say FY'25, do you expect a growth in top line?